Search

Your search keyword '"Pastorello, E A"' showing total 348 results
Start Over Author "Pastorello, E A"
348 results on '"Pastorello, E A"'

51. House dust mite allergy and shrimp allergy: a complex interaction

Author

Celi, G, Brusca, I, Scala, E, Villalta, D, Pastorello, E, Farioli, L, Cortellini, G, Deleonardi, G, Galati, P, Losappio, L, Manzotti, G, Pirovano, B, Muratore, L, Murzilli, F, Cucinelli, F, Musarra, Teresa, Cilia, M, Nucera, Eleonora, Aruanno, A, Ria, Francesco, Patria, M F, Varin, E, Polillo, B R, Sargentini, V, Quercia, O, Uasuf, C G, Zampogna, S, Carollo, M, Graci, S, Asero, R, Musarra, A, Nucera, E (ORCID:0000-0002-0565-7680), Ria, F (ORCID:0000-0002-8444-0307), Celi, G, Brusca, I, Scala, E, Villalta, D, Pastorello, E, Farioli, L, Cortellini, G, Deleonardi, G, Galati, P, Losappio, L, Manzotti, G, Pirovano, B, Muratore, L, Murzilli, F, Cucinelli, F, Musarra, Teresa, Cilia, M, Nucera, Eleonora, Aruanno, A, Ria, Francesco, Patria, M F, Varin, E, Polillo, B R, Sargentini, V, Quercia, O, Uasuf, C G, Zampogna, S, Carollo, M, Graci, S, Asero, R, Musarra, A, Nucera, E (ORCID:0000-0002-0565-7680), and Ria, F (ORCID:0000-0002-8444-0307)

Abstract

Summary:Background and Objective. Sensitization and allergy to shrimp among Italian house dust mite allergic patients are not well defined and were investigated in a large multicenter study. Methods. Shrimp sensitization and allergy were assessed in 526 house dust mite (HDM)-allergic patients submitted to the detection of IgE to Der p 10 and 100 atopic control not sensitized to HDM. Results. Shrimp allergy occurred in 9% of patients (vs 0% of 100 atopic controls not sensitized to HDM; p minor 0.001). Shrimp-allergic patients were less frequently hypersensitive to airborne allergens other than HDM than crustacean-tolerant subjects (35% vs 58.8%; p minor 0.005). Only 51% of tropomyosin-sensitized patients had shrimp allergy, and these showed significantly higher Der p 10 IgE levels than shrimp-tolerant ones (mean 22.2 KU/l vs 6.2 KU/l; p minor 0.05). Altogether 53% of shrimp-allergic patients did not react against tropomyosin. Conclusions. Shrimp allergy seems to occur uniquely in association with hypersensitivity to HDM allergens and tropomyosin is the main shrimp allergen but not a major one, at least in Italy. Along with tropomyosin-specific IgE levels, monosensitization to HDM seems to represent a risk factor for the development of shrimp allergy among HDM allergic patients.

Published
2019

54. Mast cells and acute coronary syndromes: Relationship between serum tryptase, clinical outcome and severity of coronary artery disease

Author

Morici, N, Farioli, L, Losappio, L, Colombo, G, Nichelatti, M, Preziosi, D, Micarelli, G, Oliva, F, Giannattasio, C, Klugmann, S, Pastorello, E, Pastorello, E., COLOMBO, GIULIA, GIANNATTASIO, CRISTINA, Morici, N, Farioli, L, Losappio, L, Colombo, G, Nichelatti, M, Preziosi, D, Micarelli, G, Oliva, F, Giannattasio, C, Klugmann, S, Pastorello, E, Pastorello, E., COLOMBO, GIULIA, and GIANNATTASIO, CRISTINA

Abstract

Objective: To assess the relationship between serum tryptase and the occurrence of major cardiovascular and cerebrovascular events (MACCE) at 2-year followup in patients admitted with acute coronary syndrome (ACS). To compare serum tryptase to other validated prognostic markers (maximum high-sensitivity troponin (hs-Tn), C reactive protein (CRP) levels at admission, Synergy between percutaneous coronary intervention with Taxus and Cardiac Surgery (SYNTAX) score). Methods: We measured serum tryptase at admission in 140 consecutive patients with ACS and in 50 healthy controls. The patients' follow-up was maintained for 2 years after discharge. The predictive accuracy of serum tryptase for 2-year MACCE was assessed and compared with hs-Tn, CRP and SYNTAX score. Results: Serum tryptase levels at admission were significantly higher in patients with ACS compared with the control group (p=0.0351). 2 years after discharge, 28/140 patients (20%) experienced MACCE. Serum tryptase levels, maximum hs-Tn measurements and SYNTAX score were higher in patients who experienced MACCE compared with those without (p<0.0001). Conversely, we found no significant association between MACCE and CRP. The predictive accuracy of serum tryptase for MACCE was set at the cut-off point of 6.7 ng/mL (sensitivity 46%, specificity 84%). Conclusions: In patients with ACS, serum tryptase measured during index admission is significantly correlated to the development of MACCE up to 2 years, demonstrating a possible long-term prognostic role of this biomarker.

Published
2016

58. New allergens in fruits and vegetables

Author

Pastorello, E. A., Incorvaia, C., Pravettoni, V., Farioli, L., Conti, A., Viganò, G., Rivolta, F., Ispano, M., Rotondo, F., and Ortolani, C.

Published
1998

72. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic overview of systematic reviews

Author

Nurmatov, U. Dhami, S. Arasi, S. Roberts, G. Pfaar, O. Muraro, A. Ansotegui, I.J. Calderon, M. Cingi, C. Durham, S. Van Wijk, R.G. Halken, S. Hamelmann, E. Hellings, P. Jacobsen, L. Knol, E. Larenas-Linnemann, D. Lin, S.Y. Maggina, V. Oude-Elberink, H. Pajno, G. Panwankar, R. Pastorello, E. Pitsios, C. Rotiroti, G. Timmermans, F. Tsilochristou, O. Varga, E.-M. Wilkinson, J. Williams, A. Worm, M. Zhang, L. Sheikh, A.

Abstract

Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis (ARC). To inform the development of recommendations, we sought to critically assess the systematic review evidence on the effectiveness, safety and cost-effectiveness of AIT for ARC. Methods: We undertook a systematic overview, which involved searching nine international biomedical databases from inception to October 31, 2015. Studies were independently screened by two reviewers against pre-defined eligibility criteria and critically appraised using the Critical Appraisal Skills Programme (CASP) Systematic Review Checklist for systematic reviews. Data were descriptively synthesized. Results: Our searches yielded a total of 5932 potentially eligible studies, from which 17 systematic reviews met our inclusion criteria. Eight of these were judged to be of high, five moderate and three low quality. These reviews suggested that, in carefully selected patients, subcutaneous (SCIT) and sublingual (SLIT) immunotherapy resulted in significant reductions in symptom scores and medication requirements. Serious adverse outcomes were rare for both SCIT and SLIT. Two systematic reviews reported some evidence of potential cost savings associated with use of SCIT and SLIT. Conclusions: We found moderate-to-strong evidence that SCIT and SLIT can, in appropriately selected patients, reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and protocols studied. There is a lack of data on the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT. We are now systematically reviewing all the primary studies, including recent evidence that has not been incorporated into the published systematic reviews. © 2017 The Author(s).

Published
2017

73. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis

Author

Dhami, S. Nurmatov, U. Arasi, S. Khan, T. Asaria, M. Zaman, H. Agarwal, A. Netuveli, G. Roberts, G. Pfaar, O. Muraro, A. Ansotegui, I.J. Calderon, M. Cingi, C. Durham, S. van Wijk, R.G. Halken, S. Hamelmann, E. Hellings, P. Jacobsen, L. Knol, E. Larenas-Linnemann, D. Lin, S. Maggina, P. Mösges, R. Oude Elberink, H. Pajno, G. Panwankar, R. Pastorello, E. Penagos, M. Pitsios, C. Rotiroti, G. Timmermans, F. Tsilochristou, O. Varga, E.-M. Schmidt-Weber, C. Wilkinson, J. Williams, A. Worm, M. Zhang, L. Sheikh, A.

Abstract

Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis. To inform the development of clinical recommendations, we undertook a systematic review to assess the effectiveness, cost-effectiveness, and safety of AIT in the management of allergic rhinoconjunctivitis. Methods: We searched nine international biomedical databases for published, in-progress, and unpublished evidence. Studies were independently screened by two reviewers against predefined eligibility criteria and critically appraised using established instruments. Our primary outcomes of interest were symptom, medication, and combined symptom and medication scores. Secondary outcomes of interest included cost-effectiveness and safety. Data were descriptively summarized and then quantitatively synthesized using random-effects meta-analyses. Results: We identified 5960 studies of which 160 studies satisfied our eligibility criteria. There was a substantial body of evidence demonstrating significant reductions in standardized mean differences (SMD) of symptom (SMD −0.53, 95% CI −0.63, −0.42), medication (SMD −0.37, 95% CI −0.49, −0.26), and combined symptom and medication (SMD −0.49, 95% CI −0.69, −0.30) scores while on treatment that were robust to prespecified sensitivity analyses. There was in comparison a more modest body of evidence on effectiveness post-discontinuation of AIT, suggesting a benefit in relation to symptom scores. Conclusions: AIT is effective in improving symptom, medication, and combined symptom and medication scores in patients with allergic rhinoconjunctivitis while on treatment, and there is some evidence suggesting that these benefits are maintained in relation to symptom scores after discontinuation of therapy. © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2017

74. Dominant muscular dystrophy with a novel SYNE1 gene mutation

Author

Fanin M, Savarese M, Nascimbeni AC, Di Fruscio G, Pastorello E, Tasca E, Trevisan CP, Angelini C., NIGRO, Vincenzo, Fanin, M, Savarese, M, Nascimbeni, Ac, Di Fruscio, G, Pastorello, E, Tasca, E, Trevisan, Cp, Nigro, Vincenzo, and Angelini, C.

Published
2015

75. Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

Author

Novelli, Federica, Latorre, Matteo, Vergura, Letizia, Caiaffa, Maria Filomena, Camiciottoli, Gianna, Guarnieri, Gabriella, Matucci, Andrea, Macchia, Luigi, Vianello, Andrea, Vultaggio, Alessandra, Celi, Alessandro, Cazzola, Mario, Paggiaro, Pierluigi, Camiciottoli, G., Maselli, R., Pelaia, G., Busceti, M. T., Sabato, E., Cagnazzo, M. G., Colombo, F., Palumbo, Laura, Ravazzi, Aldo, Bucca, C., Caiaffa, M. F., Berra, A., Calabrese, C., Stanziola, A. A., Schino, P., Di Gioacchino, M., Cazzola, M., Segreti, A., Pastorello, E. A., Scibilia, G., Vianello, A., Marchi, M. R., Paladini, L., Baglioni, S., Abbritti, M., Almerigogna, F., Matucci, A., Vultaggio, A., Maggi, E., Maestrelli, P., Guarnieri, G., Steinhilber, G., Bonavia, M., Rottoli, P., Bargagli, E., Senna, G., Caminati, M., Macchia, L., Bellia, V., Scichilone, N., Paggiaro, P., Novelli, F., Vergura, L., Novelli F., Latorre M., Vergura L., Caiaffa M.F., Camiciottoli G., Guarnieri G., Matucci A., Macchia L., Vianello A., Vultaggio A., Celi A., Cazzola M., Paggiaro P., Maselli R., Pelaia G., Busceti M.T., Sabato E., Cagnazzo M.G., Colombo F., Palumbo L., Ravazzi A., Bucca C., Berra A., Calabrese C., Stanziola A.A., Schino P., Di Gioacchino M., Segreti A., Pastorello E.A., Scibilia G., Marchi M.R., Paladini L., Baglioni S., Abbritti M., Almerigogna F., Maggi E., Maestrelli P., Steinhilber G., Bonavia M., Rottoli P., Bargagli E., Senna G., Caminati M., Bellia V., Scichilone N., Novelli, F., Latorre, M., Vergura, L., Caiaffa, M. F., Camiciottoli, G., Guarnieri, G., Matucci, A., Macchia, L., Vianello, A., Vultaggio, A., Celi, A., Cazzola, M., Paggiaro, P., Maselli, R., Pelaia, G., Busceti, M. T., Sabato, E., Cagnazzo, M. G., Colombo, F., Palumbo, L., Ravazzi, A., Bucca, C., Berra, A., Calabrese, C., Stanziola, A. A., Schino, P., Di Gioacchino, M., Segreti, A., Pastorello, E. A., Scibilia, G., Marchi, M. R., Paladini, L., Baglioni, S., Abbritti, M., Almerigogna, F., Maggi, E., Maestrelli, P., Steinhilber, G., Bonavia, M., Rottoli, P., Bargagli, E., Senna, G., Caminati, M., Bellia, V., and Scichilone, N.

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Exacerbation, Cross-sectional study, Omalizumab, Comorbidity, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Exhaled nitric oxide, Exacerbations, Comorbidities, Asthma, Control, Severity of Illness Index, Internal medicine, Severity of illness, Medicine, Anti-Asthmatic Agent, Humans, Pharmacology (medical), Anti-Asthmatic Agents, Inflammation Mediator, Respiratory Function Test, Aged, Cross-Sectional Studie, business.industry, Biochemistry (medical), Middle Aged, medicine.disease, Respiratory Function Tests, Cross-Sectional Studies, Italy, Physical therapy, Observational study, Female, Inflammation Mediators, Comorbiditie, business, medicine.drug, Human
Abstract

Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment. The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control. We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between poorly controlled and partially or well controlled asthmatics showed a statistically significant higher prevalence of some comorbidities in the first group, namely obesity, gastro-oesophageal reflux disease (GORD), aspirin intolerance and mental disorders (all p

Published
2015

76. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic overview of systematic reviews

Author

Nurmatov, U. (Ulugbek), Dhami, S. (Sangeeta), Arasi, S. (Stefania), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Durham, S. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Larenas-Linnemann, D. (Désirée), Lin, S.Y. (Sandra Y.), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), Sheikh, A. (Aziz), Nurmatov, U. (Ulugbek), Dhami, S. (Sangeeta), Arasi, S. (Stefania), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Durham, S. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Larenas-Linnemann, D. (Désirée), Lin, S.Y. (Sandra Y.), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), and Sheikh, A. (Aziz)

Published
2017
Full Text
View/download PDF

77. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis

Author

CTI, MS Dermatologie/Allergologie, Infection & Immunity, CDL Celdiagnostiek, Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., Sheikh, A., CTI, MS Dermatologie/Allergologie, Infection & Immunity, CDL Celdiagnostiek, Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., and Sheikh, A.

Published
2017

78. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews

Author

Nurmatov, U, Dhami, S, Arasi, S, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Larenas-Linnemann, D, Lin, SY, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, van den Worm, M (M.), Zhang, Lei, Sheikh, A (Aziz), Nurmatov, U, Dhami, S, Arasi, S, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Larenas-Linnemann, D, Lin, SY, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, van den Worm, M (M.), Zhang, Lei, and Sheikh, A (Aziz)

Published
2017

79. Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity

Author

Cortellini, G, Romano, Antonino, Santucci, A., Barbaud, A., Bavbek, S., Bignardi, D., Blanca, M., Bonadonna, P., Costantino, M. T., Laguna, J. J., Lombardo, Carla, Losappio, L. M., Makowska, J., Nakonechna, A., Quercia, O., Pastorello, E. A., Patella, V., Terreehorst, I., Testi, S., Cernadas, J. R., Dionicio Elera, J., Lippolis, D., Voltolini, S., Grosseto, D., Romano, Antonino (ORCID:0000-0003-3762-2084), Cortellini, G, Romano, Antonino, Santucci, A., Barbaud, A., Bavbek, S., Bignardi, D., Blanca, M., Bonadonna, P., Costantino, M. T., Laguna, J. J., Lombardo, Carla, Losappio, L. M., Makowska, J., Nakonechna, A., Quercia, O., Pastorello, E. A., Patella, V., Terreehorst, I., Testi, S., Cernadas, J. R., Dionicio Elera, J., Lippolis, D., Voltolini, S., Grosseto, D., and Romano, Antonino (ORCID:0000-0003-3762-2084)

Abstract

Background: Hypersensitivity to acetylsalicylic acid (ASA) constitutes a serious problem for subjects with coronary artery disease. In such subjects, physicians have to choose the more appropriate procedure between challenge and desensitization. As the literature on this issue is sparse, this study aimed to establish in these subjects clinical criteria for eligibility for an ASA challenge and/or desensitization. Methods: Collection and analysis of data on ASA challenges and desensitizations from 10 allergy centers, as well as consensus among the related physicians and an expert panel. Results: Altogether, 310 subjects were assessed; 217 had histories of urticaria/angioedema, 50 of anaphylaxis, 26 of nonimmediate cutaneous eruptions, and 17 of bronchospasm related to ASA/nonsteroidal anti-inflammatory drugs (NSAID) intake. Specifically, 119 subjects had index reactions to ASA doses lower than 300 mg. Of the 310 subjects, 138 had an acute coronary syndrome (ACS), 101 of whom underwent desensitizations, whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent challenges. Overall, 163 subjects underwent challenges and 147 subjects underwent desensitizations; 86 of the latter had index reactions to ASA doses of 300 mg or less. Ten subjects reacted to challenges, seven at doses up to 500 mg, three at a cumulative dose of 110 mg. The desensitization failure rate was 1.4%. Conclusions: In patients with stable CIHD and histories of nonsevere hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable. Patients with an ACS and histories of hypersensitivity reactions to ASA, especially following doses lower than 100 mg, should directly undergo desensitization.

Published
2017

80. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies

Author

Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haahtela, Tari Markku Kallevi, Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., Bousquet, J., Clinicum, and Department of Dermatology, Allergology and Venereology

Subjects
EIP on AHA, EAACI POSITION PAPER, RUSH IMMUNOTHERAPY, GRASS-POLLEN ALLERGY, INTERNATIONAL CONSENSUS, EUROPEAN INNOVATION PARTNERSHIP, NATIONAL DATABASES, ORAL IMMUNOTHERAPY, Asthma, Ageing, AIRWAYS ICPs, SUBLINGUAL IMMUNOTHERAPY, PRECISION MEDICINE, IMMUNOLOGY/PRACTALL CONSENSUS REPORT, 3121 General medicine, internal medicine and other clinical medicine, Allergen immunotherapy, Rhinitis
Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

81. NOTIZIE

Author

Camerani, V., Pastorello, E., and Ridolfi, Roberto

Published
1957

85. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies

Author

Calderon, MA, Demoly, P, Casale, T, Akdis, CA, Bachert, C, Bewick, M, Bilo, BM, Bohle, B, Bonini, S, Bush, A, Caimmi, DP, Canonica, GW, Cardona, V, Chiriac, AM, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, SR, Eng, P, Fiocchi, A, Fox, AT, Van Wijk, RG, Gomez, RM, Haathela, T, Halken, S, Hellings, PW, Jacobsen, L, Just, J, Tanno, LK, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, DE, Linneberg, A, Matricardi, M, Malling, HJ, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Rodriguez del Rio, P, Rueff, R, Samolinski, B, Scadding, GK, Senti, G, Shamji, MH, Sheikh, A, Sisul, JC, Sole, D, Sturm, GJ, Tabar, A, Van Ree, R, Ventura, MT, Vidal, C, Varga, EM, Worm, M, Zuberbier, T, Bousquet, J, Internal Medicine, and Medical Research Council (MRC)

Subjects
Pulmonary and Respiratory Medicine, EIP on AHA, Science & Technology, EAACI POSITION PAPER, RUSH IMMUNOTHERAPY, Allergy, GRASS-POLLEN ALLERGY, INTERNATIONAL CONSENSUS, EUROPEAN INNOVATION PARTNERSHIP, Immunology, NATIONAL DATABASES, ORAL IMMUNOTHERAPY, Ageing, AIRWAYS ICPs, Allergen immunotherapy, Asthma, Rhinitis, Immunology and Allergy, SUBLINGUAL IMMUNOTHERAPY, PRECISION MEDICINE, IMMUNOLOGY/PRACTALL CONSENSUS REPORT, Medicine and Health Sciences, Life Sciences & Biomedicine
Abstract

European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, European Structural and Development Funds of Region Languedoc Roussillon Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Hosp NHS, London, England UPMC Paris 06, Sorbonne Univ,Dept Pneumol & Addictol,UMR S 1136, Hop Arnaud de Villeneuve,CHRU Montpellier, IPLESP,Equipe EPAR,Unite Allergol, F-75013 Paris, France Univ S Florida, Morsani Coll Med, Tampa, FL USA Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland Univ Hosp Ghent, ENT Dept, Upper Airways Res Lab URL, Ghent, Belgium IQ4U Consultants Ltd, London, England Osped Riuniti, Univ Hosp, Allergy Unit, Dept Internal Med, Ancona, Italy Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria Univ Naples 2, Rome, Italy CNR, IFT, Rome, Italy Univ Genoa, Allergy & Resp Dis Clin, DIMI, IRCCS AOU San Martino IST, Genoa, Italy Hosp Univ Vall dHebron, Allergy Sect, Dept Internal Med, Barcelona, Spain Montpellier UPMC Univ Paris 06, Sorbonne Univ,UMRS 1136, Hop Arnaud de Villeneuve,Equipe EPAR IPLESP, Div Allergy,Dept Pulmonol,Univ Hosp Montpellier, Paris, France Nova Southeastern Univ, Ft Lauderdale, FL USA Univ Hosp Strasbourg, Div Allergy, Chest Dis Dept, Strasbourg, France Univ Versailles St Quentin, Suresnes, France Foch Hosp, Dept Airway Dis, Clin Pharmacol Unit, UPRES EA 220, Suresnes, France Rangueil Larrey Hosp, Dept Resp Dis, Toulouse, France Univ Palermo, Di Bi MIS, Palermo, Italy Kings Coll London, Guys & St Thomas NHS Trust, London, England Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England Childrens Hosp, Dept Pediat Pulmonol & Allergy, Aarau, Switzerland Bambino Gesu Pediat Hosp, Dept Pediat, Div Allergy, Rome, Italy Kings Coll London, Allergy Acad, London, England Erasmus MC, Dept Internal Med, Bldg Rochussenstr, Rotterdam, Netherlands Hosp San Bernardo, Unidad Alergia & Asma, Salta, Argentina Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland Odense Univ Hosp, Hans Christian Andersen Childrens Hosp, Odense, Denmark Katholieke Univ Leuven, Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Louvain, Belgium Secretary Immunotherapy Interest Grp EAACI, Allergy Learning & Consulting, Copenhagen, Denmark UPMC Univ Paris, Sorbonne Univ,Hop Enfants Armand Trousseau,INSERM, Inst Pierre Louis Epidemiol & Sante Publ,Equipe E, Allergol Dept,Ctr Asthme & Allergies,UMR S 1136, Paris, France Hosp Sirio Libanes, Sao Paulo, Brazil Univ Hosp Montpellier, Montpellier, France UPMC Paris 06, Sorbonne Univ, Equipe EPAR, UMR S 1136,IPLESP, Paris, France Ackermann Hanf & Kleine Tebbe, Outpatient Clin & Clin Res Ctr, Allergy & Asthma Ctr Westend, Berlin, Germany German Soc Otorhinolaryngol HNS, Ctr Rhinol & Allergol, Wiesbaden, Germany Univ Med Ctr Utrecht, Dept Immunol & Dermatol Allergol, Utrecht, Netherlands Med Univ Lodz, Lodz, Poland ARIA, Mexico City, DF, Mexico Hosp Med Sur, AAAAI, Mexico City, DF, Mexico Capital Reg Denmark, Res Ctr Prevent & Hlth, Copenhagen, Denmark Rigshosp, Dept Clin Expt Res, Copenhagen, Denmark Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark Charite Med Univ, Pediat Pneumol & Immunol, Berlin, Germany Gentofte Univ Hosp, Allergy Clin, Danish Allergy Ctr, Hellerup, Denmark Klinikum Univ Koln AoR, IMSIE, Cologne, Germany Hosp Clin Barcelona, Unitat Rinol & Clin Olfacte, ENT Dept, Clin & Expt Resp Immunoallergy,IDIBAPS,CIBERES, Barcelona, Catalonia, Spain Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy Univ Athens, Allergy Unit, Pediat Clin 2, Athens, Greece Univ Genoa, Allergy & Resp Dis, IRCCS San Martino IST, Genoa, Italy ASST Grande Osped Metropolitano Niguarda, Pzza Osped Maggiore, Milan, Italy Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany Heidelberg Univ, Med Fac Mannheim, Heidelberg, Germany Ctr Rhinol & Allergol, Wiesbaden, Germany Univ Aberdeen, Acad Primary Care, Div Appl Hlth Sci, Primary Care Resp Med, Aberdeen, Scotland RiRL, Cambridge, England Optimum Patient Care Ltd, Singapore, Singapore Hosp Infantil Univ Nino Jesus, Allergy Sect, Madrid, Spain Ludwig Maximillian Univ, Dept Dermatol & Allergol, Munich, Germany Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland Royal Natl Throat Nose & Ear Hosp, London, England UCL, London, England Univ Zurich Hosp, Clin Trials Ctr, Zurich, Switzerland Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Inflammat Repair & Dev Sec, Immunomodulat & Tolerance Grp,Fac Med, London, England MRC, London, England Asthma UK Ctr Allerg Mechanisms Asthma, London, England Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Asthma UK Ctr Appl Res, Med Informat Ctr, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland SLAAI, Asuncion, Paraguay Univ Fed Sao Paulo, Programa Posgrad Pediat & Ciencias Aplicadas Pedi, Dept Pediat EPM, Sao Paulo, Brazil Med Univ Graz, Dept Dermatol & Venerol, Graz, Austria Allergy Outpatient Clin Reumannplatz, Vienna, Austria Complejo Hosp Navarra, Serv Alergol, Pamplona, Spain Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Interdisciplinary Dept Med, Bari, Italy Complejo Hosp Univ Santiago de Compostela, Dept Allergy, Santiago De Compostela, Spain Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria Charite Univ Med Berlin, Klin Dermatol Venerol & Allergol, Allergie Ctr Charite, Berlin, Germany European Innovat Partnership Act & Hlth Ageing Re, MAlad Chron Vleillissement Actif Languedoc Roussi, Paris, France INSERM, VIMA, Epidemiol & Publ Hlth Approaches, U1168,Ageing & Chron Dis, Paris, France Univ Versailles St Quentin En Yvelines, UVSQ, UMR S 1168, Versailles, France CHRU, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France Programa de Pòs‑Graduação em Pediatria e Ciências Aplicadas à Pediatria, Departamento de Pediatria EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil Web of Science

Published
2016

86. Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies

Author

Calderon, M.A. Demoly, P. Casale, T. Akdis, C.A. Bachert, C. Bewick, M. Bilò, B.M. Bohle, B. Bonini, S. Bush, A. Caimmi, D.P. Canonica, G.W. Cardona, V. Chiriac, A.M. Cox, L. Custovic, A. De Blay, F. Devillier, P. Didier, A. Di Lorenzo, G. Du Toit, G. Durham, S.R. Eng, P. Fiocchi, A. Fox, A.T. Van Wijk, R.G. Gomez, R.M. Haathela, T. Halken, S. Hellings, P.W. Jacobsen, L. Just, J. Tanno, L.K. Kleine-Tebbe, J. Klimek, L. Knol, E.F. Kuna, P. Larenas-Linnemann, D.E. Linneberg, A. Matricardi, M. Malling, H.J. Moesges, R. Mullol, J. Muraro, A. Papadopoulos, N. Passalacqua, G. Pastorello, E. Pfaar, O. Price, D. Del Rio, P.R. Ruëff, R. Samolinski, B. Scadding, G.K. Senti, G. Shamji, M.H. Sheikh, A. Sisul, J.C. Sole, D. Sturm, G.J. Tabar, A. Van Ree, R. Ventura, M.T. Vidal, C. Varga, E.M. Worm, M. Zuberbier, T. Bousquet, J.

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. © 2016 The Author(s).

Published
2016

88. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Author

Roberts, G., primary, Pfaar, O., additional, Akdis, C. A., additional, Ansotegui, I. J., additional, Durham, S. R., additional, Gerth van Wijk, R., additional, Halken, S., additional, Larenas‐Linnemann, D., additional, Pawankar, R., additional, Pitsios, C., additional, Sheikh, A., additional, Worm, M., additional, Arasi, S., additional, Calderon, M. A., additional, Cingi, C., additional, Dhami, S., additional, Fauquert, J. L., additional, Hamelmann, E., additional, Hellings, P., additional, Jacobsen, L., additional, Knol, E. F., additional, Lin, S. Y., additional, Maggina, P., additional, Mösges, R., additional, Oude Elberink, J. N. G., additional, Pajno, G. B., additional, Pastorello, E. A., additional, Penagos, M., additional, Rotiroti, G., additional, Schmidt‐Weber, C. B., additional, Timmermans, F., additional, Tsilochristou, O., additional, Varga, E.‐M., additional, Wilkinson, J. N., additional, Williams, A., additional, Zhang, L., additional, Agache, I., additional, Angier, E., additional, Fernandez‐Rivas, M., additional, Jutel, M., additional, Lau, S., additional, van Ree, R., additional, Ryan, D., additional, Sturm, G. J., additional, and Muraro, A., additional

Published
2017
Full Text
View/download PDF

89. THE ITALIAN MASTOCYTOSIS REGISTRY: THE FIRST FIVE YEARS

Author

Merante, S., Neri, I., Magliacane, D., Fortina, A. Belloni, Ingeborg, F., Pastorello, E. A., Mauro, M., Minelli, R., Difonzo, E. D. Elisa, Guggiari, E., Peserico, A., Romani, I., Bocchia, M., Fontana, E., Di Nuzzo, S., Elli, E. M., Elena, C., Virginia Valeria Ferretti, Brazzelli, V., Ciccocioppo, R., Di Stefano, M., Bossi, G., Boveri, E., Virdi, A., and Triggiani, M.

Published
2015

90. EAACI Molecular Allergology User's Guide

Author

Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

91. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Published
2016

92. Allergy immunotherapy across the life cycle to promote active and healthy ageing

Author

University of Helsinki, Clinicum, Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haahtela, Tari Markku Kallevi, Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., Bousquet, J., University of Helsinki, Clinicum, Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haahtela, Tari Markku Kallevi, Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., and Bousquet, J.

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

93. Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies

Author

Calderon, M. (Moises), Demoly, P., Casale, T.B. (Thomas), Akdis, C.A., Bachert, C. (Claus), Bewick, M., Bilò, B.M., Bohle, B. (B.), Bonini, S. (Sergio), Bush, A. (Andrew), Caimmi, D.P., Canonica, G. (Gwalter), Cardona, D. (Doris), Chiriac, A.M. (A.), Cox, L. (Linda), Custovic, A. (Adnan), Blay, F. de, Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G. (George), Durham, S.R. (Stephen), Eng, C. (Charis), Fiocchi, A. (Alessandro), Fox, A.T., Gerth van Wijk, R. (Roy), Gomez, R.M., Haathela, T., Halken, S. (Susanne), Hellings, P.W. (Peter), Jacobsen, L., Just, P.M., Tanno, L.K., Kleine-Tebbe, J. (Jörg), Klimek, L. (Ludger), Knol, E.F. (Edward Frank), Kuna, P. (Piotr), Larenas-Linnemann, D. (Désirée), Linneberg, A. (Allan), Matricardi, M., Malling, H.-J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G. (Giovanni), Pastorello, E., Pfaar, O. (Oliver), Price, D. (David), Del Rio, P.R. (P. Rodriguez), Ruëff, R., Samolinski, B., Scadding, G.K., Senti, G., Shamji, M.H., Sheikh, A. (Aziz), Sisul, J.C. (J.), Solé, D. (D.), Sturm, G.J., Tabar, A., Van Ree, R., Ventura, M.T., Vidal, C. (Carmen), Varga, E.M., Worm, M. (M.), Zuberbier, T. (Torsten), Bousquet, J. (Jean), Calderon, M. (Moises), Demoly, P., Casale, T.B. (Thomas), Akdis, C.A., Bachert, C. (Claus), Bewick, M., Bilò, B.M., Bohle, B. (B.), Bonini, S. (Sergio), Bush, A. (Andrew), Caimmi, D.P., Canonica, G. (Gwalter), Cardona, D. (Doris), Chiriac, A.M. (A.), Cox, L. (Linda), Custovic, A. (Adnan), Blay, F. de, Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G. (George), Durham, S.R. (Stephen), Eng, C. (Charis), Fiocchi, A. (Alessandro), Fox, A.T., Gerth van Wijk, R. (Roy), Gomez, R.M., Haathela, T., Halken, S. (Susanne), Hellings, P.W. (Peter), Jacobsen, L., Just, P.M., Tanno, L.K., Kleine-Tebbe, J. (Jörg), Klimek, L. (Ludger), Knol, E.F. (Edward Frank), Kuna, P. (Piotr), Larenas-Linnemann, D. (Désirée), Linneberg, A. (Allan), Matricardi, M., Malling, H.-J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G. (Giovanni), Pastorello, E., Pfaar, O. (Oliver), Price, D. (David), Del Rio, P.R. (P. Rodriguez), Ruëff, R., Samolinski, B., Scadding, G.K., Senti, G., Shamji, M.H., Sheikh, A. (Aziz), Sisul, J.C. (J.), Solé, D. (D.), Sturm, G.J., Tabar, A., Van Ree, R., Ventura, M.T., Vidal, C. (Carmen), Varga, E.M., Worm, M. (M.), Zuberbier, T. (Torsten), and Bousquet, J. (Jean)

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016
Full Text
View/download PDF

94. Allergen immunotherapy for allergic rhinoconjunctivitis: Protocol for a systematic review

Author

Dhami, S. (Sangeeta), Nurmatov, U. (Ulugbek), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Demoly, P., Durham, S.R. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Linnemann, D.L. (D. Larenas), Lin, S. (Sandra), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), Sheikh, A. (Aziz), Dhami, S. (Sangeeta), Nurmatov, U. (Ulugbek), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Demoly, P., Durham, S.R. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Linnemann, D.L. (D. Larenas), Lin, S. (Sandra), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), and Sheikh, A. (Aziz)

Abstract

Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Allergic Rhinoconjunctivitis. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic rhinoconjunctivitis. Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently scree

Published
2016
Full Text
View/download PDF

95. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Published
2016

96. EAACI Molecular Allergology User's Guide

Author

MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

97. Allergy immunotherapy across the life cycle to promote active and healthy ageing:from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, E F, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, E F, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

98. EAACI molecular allergology user's guide

Author

Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H.J., Valenta, R, Hilger, C, Hofmaier, S, Aalberse, R C, Agache, I, Asero, R, Ballmer-Weber, B, Barber, D, Beyer, K, Biedermann, T, Bilò, M B, Blank, S, Bohle, B, Bosshard, P P, Breiteneder, H, Brough, H A, Caraballo, L, Caubet, J C, Crameri, R, Davies, J M, Douladiris, N, Ebisawa, M, EIgenmann, P A, Fernandez-Rivas, M, Ferreira, F, Gadermaier, G, Glatz, M, Hamilton, R G, Hawranek, T, Hellings, P, Hoffmann-Sommergruber, K, Jakob, T, Jappe, U, Jutel, M, Kamath, S D, Knol, E F, Korosec, P, Kuehn, A, Lack, G, Lopata, A L, Mäkelä, M, Morisset, M, Niederberger, V, Nowak-Węgrzyn, A H, Papadopoulos, N G, Pastorello, E A, Pauli, G, Platts-Mills, T, Posa, D, Poulsen, L. K., Raulf, M, Sastre, J, Scala, E, Schmid, J M, Schmid-Grendelmeier, P, van Hage, M, van Ree, R, Vieths, S, Weber, R, Wickman, M, Muraro, A, Ollert, M., Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H.J., Valenta, R, Hilger, C, Hofmaier, S, Aalberse, R C, Agache, I, Asero, R, Ballmer-Weber, B, Barber, D, Beyer, K, Biedermann, T, Bilò, M B, Blank, S, Bohle, B, Bosshard, P P, Breiteneder, H, Brough, H A, Caraballo, L, Caubet, J C, Crameri, R, Davies, J M, Douladiris, N, Ebisawa, M, EIgenmann, P A, Fernandez-Rivas, M, Ferreira, F, Gadermaier, G, Glatz, M, Hamilton, R G, Hawranek, T, Hellings, P, Hoffmann-Sommergruber, K, Jakob, T, Jappe, U, Jutel, M, Kamath, S D, Knol, E F, Korosec, P, Kuehn, A, Lack, G, Lopata, A L, Mäkelä, M, Morisset, M, Niederberger, V, Nowak-Węgrzyn, A H, Papadopoulos, N G, Pastorello, E A, Pauli, G, Platts-Mills, T, Posa, D, Poulsen, L. K., Raulf, M, Sastre, J, Scala, E, Schmid, J M, Schmid-Grendelmeier, P, van Hage, M, van Ree, R, Vieths, S, Weber, R, Wickman, M, Muraro, A, and Ollert, M.

Abstract

The availability of allergen molecules ('components') from several protein families has advanced our understanding of immunoglobulin E (IgE)-mediated responses and enabled 'component-resolved diagnosis' (CRD). The European Academy of Allergy and Clinical Immunology (EAACI) Molecular Allergology User's Guide (MAUG) provides comprehensive information on important allergens and describes the diagnostic options using CRD. Part A of the EAACI MAUG introduces allergen molecules, families, composition of extracts, databases, and diagnostic IgE, skin, and basophil tests. Singleplex and multiplex IgE assays with components improve both sensitivity for low-abundance allergens and analytical specificity; IgE to individual allergens can yield information on clinical risks and distinguish cross-reactivity from true primary sensitization. Part B discusses the clinical and molecular aspects of IgE-mediated allergies to foods (including nuts, seeds, legumes, fruits, vegetables, cereal grains, milk, egg, meat, fish, and shellfish), inhalants (pollen, mold spores, mites, and animal dander), and Hymenoptera venom. Diagnostic algorithms and short case histories provide useful information for the clinical workup of allergic individuals targeted for CRD. Part C covers protein families containing ubiquitous, highly cross-reactive panallergens from plant (lipid transfer proteins, polcalcins, PR-10, profilins) and animal sources (lipocalins, parvalbumins, serum albumins, tropomyosins) and explains their diagnostic and clinical utility. Part D lists 100 important allergen molecules. In conclusion, IgE-mediated reactions and allergic diseases, including allergic rhinoconjunctivitis, asthma, food reactions, and insect sting reactions, are discussed from a novel molecular perspective. The EAACI MAUG documents the rapid progression of molecular allergology from basic research to its integration into clinical practice, a quantum leap in the management of allergic patients.

Published
2016

99. Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review

Author

Dhami, S, Nurmatov, U, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Demoly, P, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Linnemann, DL, Lin, S, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, Worm, M, Zhang, L, Sheikh, A (Aziz), Dhami, S, Nurmatov, U, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Demoly, P, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Linnemann, DL, Lin, S, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, Worm, M, Zhang, L, and Sheikh, A (Aziz)

Published
2016

100. EAACI Molecular Allergology User's Guide

Author

Matricardi, P. M., primary, Kleine‐Tebbe, J., additional, Hoffmann, H. J., additional, Valenta, R., additional, Hilger, C., additional, Hofmaier, S., additional, Aalberse, R. C., additional, Agache, I., additional, Asero, R., additional, Ballmer‐Weber, B., additional, Barber, D., additional, Beyer, K., additional, Biedermann, T., additional, Bilò, M. B., additional, Blank, S., additional, Bohle, B., additional, Bosshard, P. P., additional, Breiteneder, H., additional, Brough, H. A., additional, Caraballo, L., additional, Caubet, J. C., additional, Crameri, R., additional, Davies, J. M., additional, Douladiris, N., additional, Ebisawa, M., additional, EIgenmann, P. A., additional, Fernandez‐Rivas, M., additional, Ferreira, F., additional, Gadermaier, G., additional, Glatz, M., additional, Hamilton, R. G., additional, Hawranek, T., additional, Hellings, P., additional, Hoffmann‐Sommergruber, K., additional, Jakob, T., additional, Jappe, U., additional, Jutel, M., additional, Kamath, S. D., additional, Knol, E. F., additional, Korosec, P., additional, Kuehn, A., additional, Lack, G., additional, Lopata, A. L., additional, Mäkelä, M., additional, Morisset, M., additional, Niederberger, V., additional, Nowak‐Węgrzyn, A. H., additional, Papadopoulos, N. G., additional, Pastorello, E. A., additional, Pauli, G., additional, Platts‐Mills, T., additional, Posa, D., additional, Poulsen, L. K., additional, Raulf, M., additional, Sastre, J., additional, Scala, E., additional, Schmid, J. M., additional, Schmid‐Grendelmeier, P., additional, van Hage, M., additional, van Ree, R., additional, Vieths, S., additional, Weber, R., additional, Wickman, M., additional, Muraro, A., additional, and Ollert, M., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results